Abstract:Heart failure (HF) is an end-stage of many cardiac diseases and one of the main causes of death worldwide. The current management of this disease remains suboptimal. The adult mammalian heart was considered a post-mitotic organ. However, several reports suggest that it may possess modest regenerative potential. Adult cardiac progenitor cells (CPCs), the main players in the cardiac regeneration, constitute, as it may seem, a heterogenous group of cells, which remain quiescent in physiological conditions and become activated after an injury, contributing to cardiomyocytes renewal. They can mediate their beneficial effects through direct differentiation into cardiac cells and activation of resident stem cells but majorly do so through paracrine release of factors. CPCs can secrete cytokines, chemokines, and growth factors as well as exosomes, rich in proteins, lipids and non-coding RNAs, such as miRNAs and YRNAs, which contribute to reparation of myocardium by promoting angiogenesis, cardioprotection, cardiomyogenesis, anti-fibrotic activity, and by immune modulation. Preclinical studies assessing cardiac progenitor cells and cardiac progenitor cells-derived exosomes on damaged myocardium show that administration of cardiac progenitor cells-derived exosomes can mimic effects of cell transplantation. Exosomes may become new promising therapeutic strategy for heart regeneration nevertheless there are still several limitations as to their use in the clinic. Key questions regarding their dosage, safety, specificity, pharmacokinetics, pharmacodynamics and route of administration remain outstanding. There are still gaps in the knowledge on basic biology of exosomes and filling them will bring as closer to translation into clinic.

Human Pluripotent Stem Cell-Derived Cardiovascular Progenitors for Heart Regeneration

Pluripotent stem cell-based heart regeneration: from the developmental and immunological perspectives.

Engineering Human Ventricular Heart Muscles Based on a Highly Efficient System for Purification of Human Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes

Human Induced Pluripotent Stem Cell for Modeling Cardiovascular Diseases.

A heart full of stem cells: the spectrum of myocardial progenitor cells in the postnatal heart

Generation, expansion, and differentiation of cardiovascular progenitor cells from human pluripotent stem cells.

Expandable Cardiovascular Progenitor Cells Reprogrammed from Fibroblasts

Pluripotent Reprogramming and Lineage Reprogramming: Promises and Challenges in Cardiovascular Regeneration

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery

Human Pluripotent Stem Cell-Derived Cardiovascular Cells: From Developmental Biology to Therapeutic Applications

Heart Regeneration with Embryonic Cardiac Progenitor Cells and Cardiac Tissue Engineering.

Cardiac Progenitors Induced from Human Induced Pluripotent Stem Cells with Cardiogenic Small Molecule Effectively Regenerate Infarcted Hearts and Attenuate Fibrosis

Advances in the Generation of Constructed Cardiac Tissue Derived from Induced Pluripotent Stem Cells for Disease Modeling and Therapeutic Discovery

Human pluripotent stem cell-based models of heart development and disease

Heart Regeneration by Endogenous Stem Cells and Cardiomyocyte Proliferation

Cardiac regeneration: 20 years of development and update in zebrafish and mouse

Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors

Utilization of Human Induced Pluripotent Stem Cells for Cardiac Repair

Human embryonic stem cell-derived cardiovascular progenitor cells stimulate cardiomyocyte cell cycle activity via activating the PI3K/Akt pathway

Cardiac progenitor cell therapy: mechanisms of action

Unlocking cardiomyocyte renewal potential for myocardial regeneration therapy